

The opinion in support of the decision being
entered today is not binding precedent of the Board.

Paper 1

Filed by: Carol A. Spiegel
Administrative Patent Judge
Box Interference
Washington, D.C. 20231
Tel: 703-308-9797
Fax: 703-305-0942

Filed: March 7, 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES

MAILED

AVENTIS PHARMA S.A.

MAR 08 2002

Junior Party
U.S. Patent 6,127,175

PAT. & T.M. OFFICE
BOARD OF PATENT APPEALS
AND INTERFERENCES

v.

QING WANG, MITCHELL H. FINER and XIAO-CHI JIA

Junior Party,
Application 08/333,680

v.

AVENTIS PHARMA S.A.

Senior Party
Application 08/397,225

Patent Interference No. 104,830 (CAS)

NOTICE DECLARING INTERFERENCE
(37 CFR § 1.611)

Part A. Declaration of interference

An interference is declared (35 U.S.C. § 135(a)) between the above-identified parties.

Details of the application(s), patent (if any), reissue application (if any), count(s) and claims designated as corresponding or as not corresponding to the count(s) appear in Parts E and F of this NOTICE DECLARING INTERFERENCE.

Part B. Judge designated to handle the interference

Administrative Patent Judge Carol A. Spiegel has been designated to handle the interference. 37 CFR § 1.610(a).

Part C. Standing order

A Trial Section STANDING ORDER accompanies this NOTICE DECLARING INTERFERENCE. The STANDING ORDER applies to this interference.

Part D. Conference call to set dates

A telephone conference call to set dates for taking action in the interference is scheduled for **2:00 p.m. on May 15, 2002** (the call will be initiated from the PTO).

No later than **two business days** prior to the conference call, each party shall file and serve by facsimile a list of the preliminary motions the party intends to file. See § 17 of the STANDING ORDER.

A copy of a "sample" order setting times for taking action during the preliminary motion phase of the interference accompanies this NOTICE DECLARING INTERFERENCE.

Counsel are encouraged to discuss the order prior to the conference call with the view to coming to some mutual agreement as to dates for taking action. A typical preliminary motion period lasts approximately nine (9) months. Counsel should be prepared to justify any request for a shorter or longer period.

Part E. The parties involved in this interference are:

Junior Party

Named Inventors: EMMANUELLE VIGNE,
MICHEL PERRICAUDET,
JEAN-FRANÇOIS DEDIEU,
CÉCILE ORSINI,
PATRICE YEH,
MARTINE LATTA and
EDOUARD PROST

Patent: U.S. Patent 6,127,175,
issued October 3, 2000,
based on application 08/875,223,
filed July 17, 1997

Title: Cells for the Production of Recombinant Adenoviruses

Assignee: AVENTIS PHARMA S.A.

Accorded Benefit: of PCT application PCT/FR96/00088,
filed January 19, 1996

of FR application 95 10541,
filed September 8, 1995

of FR application 95 06532,
filed June 1, 1995

of FR application 95 00747,
filed January 20, 1995

Attorneys: See last page

Address: See last page

Junior party

Named Inventors: QING WANG,
MITCHELL H. FINER and
XIAO-CHI JIA

Application: 08/333,680
filed November 3, 1994

Title: Novel Adenoviral Vectors, Packaging Cell Lines,
Recombinant Adenoviruses and Methods

Assignee: CELL GENESYS, INC.

Accorded Benefit: None

Attorneys: See last page

Address: See last page

Senior Party

Named Inventors: MICHEL PERRICAUDET,
EMMANUELLE VIGNE and
PATRICE YEH

Application: 08/397,225
filed March 28, 1995

Title: Defective Adenovirus Vectors and Use thereof in Gene
Therapy

Assignee: AVENTIS PHARMA S.A.

Accorded Benefit: of PCT application PCT/FR94/00851,
filed July 8, 1994

of FR application 94/04590,
filed April 18, 1994

of FR application 93/08596,
filed July 13, 1993

Attorneys: See last page

Address: See last page

Part F. Count and claims of the parties

Count 1

The recombinant adenoviral vector of claim 46 of the '680 Wang application, wherein the two gene regions are E1 and E2A.

or

The replication defective recombinant adenovirus of claim 35 of the '225 Perricaudet application.

Count 2

The packaging cell line of claim 48 of the '680 Wang application, wherein the two gene regions are E1 and E2A

or

The cell line of claim 26 of the '225 Perricaudet application.

Count 3

The defective recombinant adenovirus of claim 33 of Vigne patent '175

or

The replication-defective recombinant adenovirus of claim 37 of the '680 Wang application

or

The replication defective recombinant adenovirus of claim 34 of the '225 Perricaudet application.

Count 4

The recombinant cell line of claim 1 of Vigne patent '175

or

The packaging cell line of claim 39 of the '680 Wang application

or

The cell line of claim 22 of the '225 Perricaudet application.

Count 5

The recombinant adenoviral vector of claim 46 of the Wang '680 application,
wherein the two gene regions are E1 and E4

or

The replication-defective adenovirus of claim 42 of the '225 Perricaudet
application.

Count 6

The packaging cell line of claim 48 of the Wang '680 application

or

The cell line of claim 24 of the Perricaudet '225 application.

The claims of the parties are:

Wang: 37-48, 52, 54, 56-57

Vigne: 1-33

Perricaudet: 1-3, 6, 9-30, 33-42

The claims of the parties which correspond to Count 1 are:

Wang: 46, 56

Vigne: None

Perricaudet: 1-3, 9, 12-18, 28, 30, 35, 40-41

The claims of the parties which correspond to Count 2 are:

Wang: 48

Vigne: None

Perricaudet: 19-20, 23, 25-27

The claims of the parties which correspond to Count 3 are:

Wang: 37-38, 46-47, 52, 54, 56
Vigne: 33
Perricaudet: 1-3, 9, 12-18, 28, 30, 34, 40-41

The claims of the parties which correspond to Count 4 are:

Wang: 39-44, 57
Vigne: 1-6, 11-16, 20-21, 23-25
Perricaudet: 19-23, 25, 27, 33

The claims of the parties which correspond to Count 5 are:

Wang: 37, 46, 54, 56
Vigne: None
Perricaudet: 42

The claims of the parties which correspond to Count 6 are:

Wang: 48, 57
Vigne: None
Perricaudet: 24

The claims of the parties which do not correspond to any of Counts 1 through 6, and therefore are not involved in the interference, are:

Wang: 45
Vigne: 7-10, 17-19, 22, 26-32
Perricaudet: 6, 10-11, 29, 36-39

Part G. Heading to be used on papers

The following heading shall be used on papers filed in the interference. See
§ 18 of the STANDING ORDER.

Paper ____¹

Filed on behalf of [name of party]

By: Name of lead counsel, Esq.
Name of backup counsel, Esq.
Street address
City, State, and Zip-Code
Tel:
Fax:

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES

AVENTIS PHARMA S.A.
Junior Party
U.S. Patent 6,127,175

v.

QING WANG, MITCHELL H. FINER and XIAO-CHI JIA

Junior Party,
Application 08/333,680

v.

AVENTIS PHARMA S.A.
Senior Party
Application 08/397,225

Patent Interference No. 104,830 (CAS)

TITLE OF PAPER

¹ Leave a blank line because the board assigns the paper number.

Part H. Summary of dates for taking action

Times for taking action are set out in the following sections of the STANDING ORDER:

1. **§ 7:** date for identifying lead and backup counsel.
2. **§ 8:** date for identifying any real party in interest.
3. **§ 9:** date for requesting copies of involved and benefit applications and patents.
4. **§ 17:** date for filing list of proposed preliminary motions.
5. **§ 19:** date for accomplishing certain discovery.
6. **§ 20:** date for filing clean copy of claims.
7. **§ 21:** date for filing clean copy of claims in cases with drawings and/or claims containing a means plus function limitation.
8. **§ 23:** dates for filing oppositions to Rule 635 miscellaneous motions and dates for filing replies to oppositions.
9. **§ 33:** date for objecting to admissibility of evidence.
10. **§ 34:** date for serving supplemental affidavits or evidence to respond to objection to admissibility of evidence.
11. **§ 35:** dates when cross-examination can take place.
12. **§ 45:** dates for taking action with respect to settlement discussions

Part I. Order form for requesting file copies

FILE COPY REQUEST

Interference 104,830 (CAS)


A copy of Part E of this NOTICE DECLARING INTERFERENCE should be attached to this FILE COPY REQUEST, with a circle by hand around the patents and applications for which a copy of a file wrapper is desired.

To facilitate processing of this FILE COPY REQUEST, the following information should be included:

1. Charge fees to USPTO Deposit Account No: _____
2. Complete address, including street, city, state, zip code and telephone number (do not list a Post Office box inasmuch as file copies are sent via commercial overnight courier).

Telephone, including area code: _____

Part J. Signature of administrative patent judge



Carol A. Spiegel
Administrative Patent Judge

Date: March 7, 2002
Arlington, VA

Enc:

Copy of STANDING ORDER

Copy of order used for setting times for taking action in the preliminary motion phase of the interference (ORDERPM6)

Copy of order used for setting times for taking action in the testimony and briefing phases of the interference (ORDERTE6)

Copy of claims of 08/333,680

Copy of claims of 08/397,225

Copy of U.S. Patent 6,127,175

DECLARE.007
Revised September, 2000
(replaces DECLARE.006.1)

cc (via Federal Express):

Attorney for Wang
(real party in interest
CELL GENESYS, INC.):

Linda R. Judge, Esq.
CELL GENESYS, INC.
322 Lakeside Drive
Foster City, CA 94404

Attorney for Vigne
(real party in interest
AVENTIS PHARMA S.A.):

Paul F. Fehlner, Esq.
RHONE-POULENC RORER INC.
P.O. Box 5093
Legal Patents #3C43
Collegeville, PA 19426-0997

Attorney for Perricaudet
(real party in interest
AVENTIS PHARMA S.A.):

David Kulik, Esq.
WILEY, REIN & FIELDING, LLP
Intellectual Property Department
1776 K Street NW
Washington, DC 20006

INTERFERENCE DIGEST

Interference No. 104,826

Paper No. 40

Name: Qing Wang et al.

Serial No.: 08/333,680

Patent No.

Title: Novel adenoviral vectors, packaging cell lines, recombinant adenovirus and methods

Filed: 11/03/94

Interference with Zhang et al.

DECISION ON MOTIONS

Administrative Patent Judge, _____ Dated, _____

FINAL DECISION

Board of Patent Appeals and Interferences, favorable Dated, 10/25/02

Court, _____ Dated, _____

REMARKS

This should be placed in each application or patent involved in interference in addition to the interference letters.